After protracted legal battling, GSK has agreed to pay up to $2.2 billion to settle most of the pending lawsuits that claimed a discontinued version of the Zantac heartburn medication caused cancer.
The company also said on Wednesday that it had reached another agreement in principle to pay $70 million to settle a separate Zantac case with US laboratory Valisure—which is still subject to ...
GSK has agreed to pay up to $2.2 billion to resolve approximately 80,000 lawsuits brought by users of Zantac who claimed the heartburn drug caused their cancer. The agreement frees the British ...
GSK’s move doesn’t end litigation around Zantac as other drugmakers are still facing trials, including Boehringer Ingelheim GmbH, which is facing a jury trial in Oakland.
GSK to pay $70 million to settle whistleblower lawsuit Pfizer and Sanofi also settling Zantac cases Boehringer Ingelheim faces trial, denies wrongdoing Oct 9 (Reuters) - GSK (GSK.L), opens new tab ...